Unlocking cellular profiling and target discovery with epitope resolution
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 06.04.2026 | Stipple Bio Raises $100M in Series A Financing | Stipple Bio, Inc., a Cambridge, MA-based biotechnology company leveraging epitope-level precision to create targeted cancer therapies, closed a $100m Series A financing.
The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest... |
| - | Stipple Bio | “Unlocking cellular profiling and target discovery with epitope resolution” |
Reviews 0
